Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5427]

Significant survival gains with atezolizumab for NSCLC

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France

Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )

Pembrolizumab plus chemo as firstline therapy for NSCLC

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

Dr Giorgio Scagliotti - University of Turin, Turin, Italy

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC...

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

Firstline pembrolizumab plus chemo improves NSCLC outcomes

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Firstline pembrolizumab plus chemo improves NSCLC outcomes ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )

KRAS in the clinic and conference

Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

KRAS in the clinic and conference ( Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Phase I results of a novel FGFR inhibitor

Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland

Phase I results of a novel FGFR inhibitor ( Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland )

Firstline pembrolizumab for metastatic urothelial cancer

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Firstline pembrolizumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )

Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer

Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France

Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer ( Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France )

FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer

Prof John Robertson - University of Nottingham, Nottingham, UK

FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer ( Prof John Robertson - University of Nottingham, Nottingham, UK )

Fulvestrant in FALCON trial improves PFS in advanced breast cancer

Dr Matthew Ellis - Washington University in St Louis, USA

Fulvestrant in FALCON trial improves PFS in advanced breast cancer ( Dr Matthew Ellis - Washington University in St Louis, USA )

Dabrafenib shows higher response and lower toxicity in paediatric brain cancer...

Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders...

Dabrafenib shows higher response and lower toxicity in paediatric brain cancer trial ( Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, USA )

More from ecancer